Published on
December 31, 2020
- 08:00 GMT
NETRIS Pharma First Patient Dosed in Phase Ib/II GYNet Study of NP137 in combination with chemotherapy and/or KEYTRUDA®
NETRIS Pharma has dosed the first patient in its GYNet Phase 1b/II clinical study of NP137 LYON, FRANCE, December 31, 2020 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage biopharmaceutical company developing therapeutics based on dependence …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
